Non-Alcoholic Fatty Liver Disease (NAFLD) is a significant global health concern, affecting approximately 25% of the world's population. Characterised by the accumulation of fat in liver cells, NAFLD can progress to more severe conditions like Non-Alcoholic Steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Understanding and managing this disease is crucial to prevent its progression and associated complications.
NAFLD is a multifactorial disease, often associated with metabolic syndrome. The pathophysiology involves insulin resistance, oxidative stress, and lipid metabolism dysregulation. Genetic predisposition, dietary habits, and gut microbiota are also significant contributing factors.
Diagnosis of NAFLD often occurs incidentally during routine blood tests or imaging studies. Elevated liver enzymes, particularly alanine aminotransferase (ALT), can hint towards NAFLD. Ultrasound is the most commonly used imaging modality, but it has limitations in detecting mild steatosis. Liver biopsy, though invasive, remains the gold standard for diagnosing and staging NAFLD.
Management of NAFLD focuses on lifestyle modifications, such as diet changes and increased physical activity, aiming to reduce weight and improve insulin resistance. Pharmacological interventions are considered for patients with NASH or fibrosis. Emerging therapies, including drugs targeting metabolic pathways and fibrosis, are under investigation.
NAFLD's prognosis depends on the stage of the disease and the presence of fibrosis. Regular follow-up with liver function tests and imaging is recommended to monitor disease progression. Patients with advanced NAFLD require surveillance for hepatocellular carcinoma.
In summary, NAFLD is a prevalent disease with potential severe outcomes. Early diagnosis and effective management strategies are vital to prevent disease progression. Ongoing research aims to improve understanding of NAFLD's pathophysiology and develop novel therapeutic interventions.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation